News
The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service ...
The manufacturers of a new weight-loss drug recently rolled out by the NHS are upping their prices by 170%. Eli Lilly is ...
Eli Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro for people who buy the drug ...
More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's ...
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...
Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...
The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results